金属正电子核素~(64)Cu,~(68)Ga,~(86)Y和~(89)Zr的PET标记药物研究进展

~(64)Cu,~(68)Ga,~(86)Y和~(89)Zr具备不同的半衰期和特殊生物体内性质,丰富了PET药物的多样性,为疾病的诊断和治疗提供了新的契机。近年来,金属正电子核素~(64)Cu,~(68)Ga,~(86)Y和~(89)Zr标记的药物在正电子发射计算机断层显像(PET)诊断中的应用越来越多,~(64)Cu在乏氧显像中发挥重要作用,~(68)Ga在靶向神经内分泌(NET)类肿瘤的诊断药物领域发展迅速,~(86)Y,~(89)Zr有望在免疫PET和放射免疫治疗领域发挥作用。本文主要综述金属正电子核素~(64)Cu,~(68)Ga,~(86)Y,~(89)Zr的生产与纯化,溶液配位化学以及应用方面的研究进展。

Positron Emission Radiometals 64Cu, 68Ga, 86Y and 89Zr Labeled PET Drugs

Positron emission radiometals 64Cu,68Ga,86Y and 89Zr have different half lives and special biological properties,not only enrich the diversity of PET drugs,but also provide a new opportunity for the diagnosis and treatment of disease.In recent years,positron emission radiometals 64Cu,68Ga,86Y and 89Zr have more and more applications in the medical diagnostics of PET (positron emission tomography).64Cu has already had a significant impact in cancer hypoxia imaging.68Ga is developing rapidly in the field of diagnosis of NET (Neuroendocrine tumor) tumor.89Zr and 86Y are expected to play a role in the field of immunoPET and radioimmunotheray.This paper briefly reviews the research progress on the production and purification,solution coordination chemistry and applications of 68Ga,86Y,89Zr and 64Cu.